Life Science

A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.

A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.

A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.

A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.

A potent and reversible proteasome inhibitor, targeting the chymotryptic site on the 20S particle (Ki = 21 nM) reduces the degradation of ubiquitin-conjugated proteins in extracts blocks the degradation of long- and short-lived proteins in intact

A potent and reversible proteasome inhibitor, targeting the chymotryptic site on the 20S particle (Ki = 21 nM) reduces the degradation of ubiquitin-conjugated proteins in extracts blocks the degradation of long- and short-lived proteins in intact

A potent, reversible, and cell permeable proteasome inhibitor inhibits cell growth in B16 and IPC227F cells with IC50 values of 42 and 77 nM, respectively inhibits NF-&kappaB activation, sensitizing a variety of carcinoma cell lines to apoptosis.

A potent, reversible, and cell permeable proteasome inhibitor inhibits cell growth in B16 and IPC227F cells with IC50 values of 42 and 77 nM, respectively inhibits NF-&kappaB activation, sensitizing a variety of carcinoma cell lines to apoptosis.

A potent, reversible, and cell permeable proteasome inhibitor inhibits cell growth in B16 and IPC227F cells with IC50 values of 42 and 77 nM, respectively inhibits NF-&kappaB activation, sensitizing a variety of carcinoma cell lines to apoptosis.

A potent, reversible, and cell permeable proteasome inhibitor inhibits cell growth in B16 and IPC227F cells with IC50 values of 42 and 77 nM, respectively inhibits NF-&kappaB activation, sensitizing a variety of carcinoma cell lines to apoptosis.

(S)-Naproxen is a non-selective COX inhibitor. The IC₅₀ values for human recombinant COX-1 and -2 are 0.6-4.8 &microM and 2.0-28.4 &microM, respectively.

(S)-Naproxen is a non-selective COX inhibitor. The IC₅₀ values for human recombinant COX-1 and -2 are 0.6-4.8 &microM and 2.0-28.4 &microM, respectively.